Medtronic has reported revenues of around $9.8bn in Q1 of fiscal year 2027 (FY27) driven by double-digit growth across its key business segments, prompting the company to raise its FY27 outlook.
With Q1 performance corresponding to year-over-year (YoY) growth of 13.7%, the medtech giant now expects organic revenue growth for FY27 to land in the 7.25% to 7.75% range, up from 6.75% to 7.25% previously, and with earnings anticipated to come in at $5.94-$6 per share versus $5.90-$6 previously.
Medtronic’s cardiovascular business was its top performer in Q1, with worldwide revenues of around $3.9bn indicative of a YoY growth margin of 19.5%. Within the segment, electrophysiology therapies (EPT), a sub-segment that includes Medtronic’s cardiac ablation solutions (CAS) such as its PulseSelect pulsed-field ablation (PFA) system and Affera mapping system, drew in…



